Home Hot keywords

Search Modes

搜索结果

2019 trial failed shares collapse edasalonexent Catabasis
2020年10月29日 — Share this article: ... Catabasis Pharmaceuticals' investigational oral therapy edasalonexent failed to preserve muscle function and overall ...
缺少字词: 2019collapse
2020年10月27日 — It's the final nail in the coffin for Catabasis Pharmaceuticals' Duchenne muscular dystrophy hopeful as edasalonexent has once again failed ...
缺少字词: 2019 ‎| 必须包含: 2019
2020年10月27日 — Boston-based Catabasis Pharmaceuticals has announced that the Phase III PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy ...
缺少字词: collapse ‎| 必须包含: collapse
Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne. Muscular Dystrophy --. CAMBRIDGE, Mass., March 14, 2019 – Catabasis ...
缺少字词: failedcollapse
2020年10月27日 — Stocks In Focus Catabasis Ends Duchenne Muscular Dystrophy Trials After Failed Late-Stage Study. Catabasis Pharmaceuticals Inc (NASDAQ: ...
缺少字词: 2019 ‎| 必须包含: 2019
作者:E Finanger2019被引用次数:30 — Keywords: Duchenne muscular dystrophy, NF-κB, edasalonexent, CAT-1004 ... with one patient failing screening due to difficulty with trial ...
2020年3月24日 — If the data is satisfactory, the PolarisDMD trial data will be used for an NDA filing in 2021. Edasalonexent has had stellar data thus far and ...
2017年1月31日 — Catabasis CEO Jill Milne said that the company would determine next steps for edasalonexent after analyzing data from an open-label extension of ...
缺少字词: 2019collapse
作者:RS Finkel2021被引用次数:1 — MoveDMD is a study of edasalonexent in boys with Duchenne muscular ... In a phase 1 trial in pediatric patients with DMD, edasalonexent was ...
2019年1月3日 — 3, 2019– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial ...
缺少字词: failedcollapse

google search trends